Prostatis Group’s iShares US Healthcare Providers ETF IHF Stock Holding History

Prostatis Group’s Portfolio IHF Stock Details IHF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-170,885	Closed	-$8.63M	–	251
2023 Q1	$8.63M	Buy	+170,885	New	+$8.78M	4.55%	8

Other funds holding IHF

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.99B AUM 30.41% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.9% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Prostatis Group's IHF Position: Q2 2023 in Review

Prostatis Group sold out of iShares US Healthcare Providers ETF (IHF) in Q2 2023, closing a stake of 170,885 shares — an estimated $8.63M sold.

Prostatis Group first reported a position in IHF in Q1 2023 and held it in 1 quarter. The position peaked at $8.63M in Q1 2023. 209 funds tracked by Wall St. Rank hold IHF as of Q2 2023.

Prostatis Group reported no remaining iShares US Healthcare Providers ETF position as of Q2 2023 after selling out during the quarter.
Prostatis Group sold 170,885 iShares US Healthcare Providers ETF shares in Q2 2023, an estimated $8.63M.
Prostatis Group first reported a position in iShares US Healthcare Providers ETF in Q1 2023 and held it in 1 quarter.
Prostatis Group's iShares US Healthcare Providers ETF position peaked at $8.63M in Q1 2023.
209 funds tracked by Wall St. Rank held iShares US Healthcare Providers ETF as of Q2 2023.

Based on Prostatis Group's 13F filing for Q2 2023, filed 14 Aug 2023.